scholarly article | Q13442814 |
P50 | author | Michael Rossmann | Q101728 |
P2093 | author name string | Moh Lan Yap | |
Taiki Aoshi | |||
Yevel Flores-Garcia | |||
Ryuji Ueno | |||
Yasunari Haseda | |||
Atsuko Sakurai | |||
Wataru Akahata | |||
Momoko Ishikawa | |||
Akane Urakami | |||
Sachiko Kuno | |||
Fidel P Zavala | |||
P2860 | cites work | Advances and challenges in malaria vaccine development | Q21032463 |
Characterization of reemerging chikungunya virus | Q21090531 | ||
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection | Q24628167 | ||
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection | Q24631774 | ||
Prime-boost immunization strategies against Chikungunya virus | Q24701774 | ||
Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures | Q41902663 | ||
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial | Q42199381 | ||
Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies | Q42219084 | ||
Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. | Q44146651 | ||
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. | Q44169635 | ||
Implementation of RTS,S/AS01 Malaria Vaccine--The Need for Further Evidence. | Q45947348 | ||
Bacterial entry to the splenic white pulp initiates antigen presentation to CD8+ T cells | Q46400132 | ||
The influence of antigen organization on B cell responsiveness | Q72628042 | ||
Self-assembling protein nanoparticles in the design of vaccines | Q26767097 | ||
Structural changes of envelope proteins during alphavirus fusion | Q27666145 | ||
Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography | Q27666147 | ||
Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. | Q27677990 | ||
Accurate determination of local defocus and specimen tilt in electron microscopy | Q27861008 | ||
EMAN2: an extensible image processing suite for electron microscopy | Q27861052 | ||
The RTS,S malaria vaccine | Q28285472 | ||
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease | Q28533408 | ||
Single particle cryo-electron microscopy and 3-D reconstruction of viruses | Q28660278 | ||
Outcome of the first electron microscopy validation task force meeting | Q28730539 | ||
Versatile virus-like particle carrier for epitope based vaccines | Q28748358 | ||
RELION: implementation of a Bayesian approach to cryo-EM structure determination | Q29547673 | ||
Automated molecular microscopy: the new Leginon system | Q29614290 | ||
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies | Q30430925 | ||
Germinal center B cells recognize antigen through a specialized immune synapse architecture. | Q30784700 | ||
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data | Q33521372 | ||
The RTS,S vaccine candidate for malaria | Q34186762 | ||
A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts | Q34261339 | ||
1 Preparation of monoclonal antibodies: Strategies and procedures | Q34284111 | ||
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization | Q34509612 | ||
Ordered just so: lipid rafts and lymphocyte function | Q34553079 | ||
Virus-like particles as immunogens | Q35295832 | ||
P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections | Q35561160 | ||
Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins | Q35591846 | ||
Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses | Q35841913 | ||
A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design | Q36171996 | ||
Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress | Q36318652 | ||
Virus-like particles: flexible platforms for vaccine development | Q36837144 | ||
The cellular niche of Listeria monocytogenes infection changes rapidly in the spleen | Q37359247 | ||
Biology and pathogenesis of chikungunya virus | Q37765475 | ||
Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design | Q37792984 | ||
Virus-like particles in vaccine development. | Q37798008 | ||
Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development | Q38059059 | ||
Pre-existing immunity against vaccine vectors--friend or foe? | Q38061876 | ||
Cellular and molecular mechanisms of chikungunya pathogenesis | Q38532733 | ||
P433 | issue | 7 | |
P921 | main subject | Chikungunya virus | Q15794049 |
P577 | publication date | 2017-05-17 | |
P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
P1476 | title | Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus | |
P478 | volume | 24 |
Q40093469 | Adjuvant formulations for virus-like particle (VLP) based vaccines |
Q56897945 | An attenuated replication-competent chikungunya virus with a fluorescently tagged envelope |
Q91354673 | Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M |
Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
Q93199923 | Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |
Search more.